# Chemed Corp (CHE) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $519.84, market value $6.8 billion.

## Valuation
- **P/E (trailing): 26.2×** (5-yr avg 28.7×, 3-yr avg 27.3×). Chemed Corp trades at 26.2× trailing earnings, close to its own five-year average of 28.7×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.9×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Price / book: 8.1×**. The shares trade at 8.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 16.4×**. Enterprise value is 16.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.8%** (5-yr avg 3.9%). Free cash flow equals 4.8% of the market value, above its five-year average of 3.9%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.8%**. The inverse of the P/E: 3.8% of the price is earned each year.

## Profitability
- **Operating margin: 13.5%**. 13.5% of revenue is left after running the business.
- **Net margin: 10.5%**. 10.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 27.1%**. 27.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 27.7%**. Return on all capital, debt included, is 27.7%: comfortably above what that capital costs.
- **Return on assets: 17.9%**. Each dollar of assets produces 17.9% of profit.

## Growth
- **Revenue growth (1 yr): 65.3%** (3-yr 28.2%/yr, 5-yr 13.6%/yr). Revenue grew 65.3% over the last year, against 13.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -7.8%** (3-yr 3.5%/yr, 5-yr -1.2%/yr). Earnings per share fell 7.8%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 8.8%/yr**. Free cash flow has compounded at 8.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.0×**. It would take 0.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 1.05** (quick 1.05). Current assets cover the next year's liabilities 1.05 times.
- **Altman Z-score: 10.57**. A Z-score of 10.57 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.54%** ($2.40 per share, trailing). Chemed Corp yields 0.54%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 12%** (10% of free cash flow). 12% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 10.8%/yr** (1-yr 22.2%). The dividend has compounded at 10.8% a year over five years, doubling roughly every 7 years at that pace.

## Price and momentum
- **Total return (1 yr): 13.5%** (YTD 21.8%, 3-mo 17.7%). The shares are up 13.5% over twelve months including dividends.
- **From 52-week high: -6.7%** (42.3% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 0.03** (volatility 29%). Beta of 0.03 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CHE · Page: https://foliofundamentals.com/stocks/che

Not investment advice.